beta
Trial Radar AI
Clinical Trial NCT07085455 for Critical Illness, Organ Dysfunction, Enteral Nutrition Intolerance, Inadequate Nutritional Intake is recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here.
One study matched filter criteria
Card View

The Effect of the Timing of Supplemental Parenteral Nutrition on the Prognosis of Critically Ill Patients (T-SPN) 946 Randomized Short-Term

Recruiting
Clinical Trial NCT07085455 is an interventional study for Critical Illness, Organ Dysfunction, Enteral Nutrition Intolerance, Inadequate Nutritional Intake that is recruiting. It started on 9 September 2025 with plans to enroll 946 participants. Led by Dong Zhang, it is expected to complete by 20 July 2029. The latest data from ClinicalTrials.gov was last updated on 15 September 2025.
Brief Summary
This multicenter, randomized controlled trial aims to evaluate whether early initiation of supplemental parenteral nutrition (SPN) (on day 4 of ICU admission) compared to late initiation (on day 8) can reduce 28-day all-cause mortality in critically ill patients. Secondary objectives include assessing the effects of early SPN on long-term functional outcomes (2-year EQ-5D-5L scores), mortality at various timepoints (...Show More
Detailed Description
This is a multicenter, randomized, controlled clinical trial designed to evaluate the impact of early supplemental parenteral nutrition (SPN) versus late SPN initiation on clinical outcomes in critically ill patients. The primary objective is to determine whether initiating SPN on day 4 of ICU admission, compared to day 8, can reduce 28-day all-cause mortality. Secondary objectives include assessing the effects of ea...Show More
Official Title

The Effect of the Timing of Supplemental Parenteral Nutrition on the Prognosis of Critically Ill Patients (T-SPN): A Multicenter Randomized Controlled Trial

Conditions
Critical IllnessOrgan DysfunctionEnteral Nutrition IntoleranceInadequate Nutritional Intake
Other Study IDs
  • T-SPN
NCT ID Number
Start Date (Actual)
2025-09-09
Last Update Posted
2025-09-15
Completion Date (Estimated)
2029-07-20
Enrollment (Estimated)
946
Study Type
Interventional
PHASE
N/A
Status
Recruiting
Keywords
Nutritional support
Supplementary parenteral nutrition
Early enteral nutrition
Severe patients
critical care
intensive care
Primary Purpose
Treatment
Design Allocation
Randomized
Interventional Model
Parallel
Masking
Single
Arms / Interventions
Participant Group/ArmIntervention/Treatment
ExperimentalEarly SPN Group
Patients in this group will receive supplemental parenteral nutrition (SPN) starting on day 4 after ICU admission, in addition to standard enteral nutrition (EN).
Early Supplemental Parenteral Nutrition (SPN)
SPN is initiated on ICU day 4 if enteral nutrition remains \<50% of the target caloric requirement. Nutrition support is guided by protocol
Active ComparatorLate SPN Group
Patients in this group will receive SPN starting on day 8 after ICU admission, in addition to standard EN.
Late Supplemental Parenteral Nutrition (SPN)
SPN is initiated on ICU day 8 if enteral nutrition remains \<50% of the target caloric requirement. Nutrition support is guided by the same protocol as in the early SPN group.
Primary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
28-Day All-Cause Mortality
Death from any cause occurring within 28 days of ICU admission. This is a binary outcome (alive or dead). Lower mortality indicates better outcome.
28 days after ICU admission
Secondary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
physical function score: EuroQol 5-Dimension 5-Level Questionnaire(EQ5D5L)
The EuroQol 5-Dimension 5-Level questionnaire (EQ-5D-5L) is a standardized instrument for measuring health-related quality of life. It includes five dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each rated on five levels, and a visual analog scale (EQ-VAS) ranging from 0 to 100. The utility index score, calculated using the country-specific value set (e.g., China), typically ranges from \<0 (worse than death) to 1 (perfect health). Higher scores indicate better health status.
28 days after ICU admission,90 days after ICU admission,180 days after ICU admission,2 years after ICU admission
ICU Length of Stay
The number of days the patient remains in the intensive care unit (ICU), counted from the date of ICU admission to the date of ICU discharge. A higher number indicates longer ICU stay.
Duration of ICU stay, from admission to discharge from ICU up to 28 days
Serum Prealbumin Levels on Day 8, Day 28, Day 90, Day 180, and 2 Years
Serum prealbumin (transthyretin) concentrations will be measured at five time points (ICU day 8, day 28, and at 90 days, 180 days, and 2 years post-ICU admission). Venous blood samples will be used for laboratory analysis. Results will be reported in mg/dL. Higher levels indicate better nutritional status and recovery.
ICU day 8, day 28, and at 90 days, 180 days, and 2 years after ICU admission
Muscle Ultrasound Measurements on Day 8, Day 28, Day 90, Day 180, and 2 Years
Muscle mass will be assessed by bedside ultrasound at five time points: ICU day 8, day 28, and at 90 days, 180 days, and 2 years post-ICU admission. Parameters include diaphragm thickness, biceps thickness, quadriceps thickness, and rectus femoris cross-sectional area. Ultrasound measurements will follow standardized anatomical landmarks and positioning. Higher values reflect greater muscle mass and better nutritional status.
ICU day 8, day 28, and at 90 days, 180 days, and 2 years after ICU admission
Incidence of New Infections in the ICU
The number of patients who develop new infections during their ICU stay. Only infections acquired after ICU admission will be counted. Definitions follow CDC/NHSN surveillance criteria, including ventilator-associated pneumonia (VAP), catheter-related bloodstream infection (CRBSI), urinary tract infection (UTI), etc. This is a binary outcome (infection: yes/no) or count variable (number of new infections).
From ICU admission to ICU discharge up to 28 days
Ventilator-Free Days Within 28 Days After ICU Admission
The number of days within the first 28 days after ICU admission during which the patient is alive and free from invasive mechanical ventilation. If the patient dies within 28 days, the ventilator-free days will be counted as 0. Higher values indicate better outcomes.
28 days after ICU admission
All-Cause Mortality at Multiple Time Points (ICU, 28days,90 days, 180 days, 2 years)
All-cause mortality will be assessed at the following time points: during ICU stay, at 28 days, at 90 days, at 180 days, and at 2 years after ICU admission. Mortality status will be determined via hospital records or telephone follow-up. Lower mortality at each time point indicates better outcome.
From ICU admission to 2 years after ICU admission
The number of participants with Laboratory Safety Parameters and Liver Dysfunction
Laboratory parameters including blood glucose, blood lipids (total cholesterol, triglycerides), serum creatinine, blood urea nitrogen, and transaminases (ALT, AST) will be measured during ICU stay and up to day 28. Liver failure will be diagnosed based on clinical and laboratory criteria (e.g., jaundice, coagulopathy, elevated transaminases and bilirubin). These indicators are used to assess metabolic tolerance and organ function related to nutrition interventions.
From ICU admission to Day 28
Participation Assistant
Eligibility Criteria

Eligible Ages
Adult, Older Adult
Minimum Age
18 Years
Eligible Sexes
All
  1. Age ≥ 18 years
  2. Failure of one or more organ systems within 24 hours of ICU admission, defined as Sequential Organ Failure Assessment (SOFA) score ≥ 2 in any single organ system
  3. Expected ICU stay > 72 hours
  4. Able to initiate early enteral nutrition (EN) within 48 hours of ICU admission

1.Full oral intake or tolerance of full-dose EN; no need for SPN 2.Receiving palliative care or expected to die within 72 hours 3.Pregnant or lactating women 4.Long-term use of systemic corticosteroids or other immunosuppressive agents 5.Known malignancy currently receiving radiotherapy or chemotherapy 6.Contraindications to parenteral nutrition (PN) 7.Participation in another interventional clinical trial
Dong Zhang logoDong Zhang
Study Responsible Party
Dong Zhang, Sponsor-Investigator, chief physician, The First Hospital of Jilin University
Study Central Contact
Contact: yanhua li, 86-15804301738, [email protected]
Contact: youquan wang, 86-15584299391, [email protected]
2 Study Locations in 1 Countries

Jilin

The First Hospital of Jilin University, Changchun, Jilin, 130021, China
yanhua li, Contact, 86-15804301738
Not yet recruiting
The First Hospital of Jilin University, Changchun, Jilin, 130021, China
Recruiting